Strong momentum remains, in both Europe and the USA
EasyVista’s Q3 sales were up 25% after 50% in H1, leading to +42% for 9 months. Though current quarters are still boosted by the change in contracting mode, organic momentum…
Strong revenue growth, but profitability still impacted by the transition phase
Currently in a transition year, the group has reported growing H1 revenue but profit, although positive, was lower than in H1 17. Keyware’s revenue was pushed by the Authorisations division,…
Refonte
La publication des comptes 2017 en Août 2018 et l’AGM de Septembre permettent de prendre la totale mesure de la transformation de Bourrelier Group d’un groupe de distribution d’équipement de…
The delayed launch of Zeneo implies a lower target price
Our EPS forecasts only move marginally in the short term and are not very significant since the company will start selling Zeneo as of 2021. They mostly depend on the…
Strong underlying operational delivery
Ecoslops’ H1 18 release highlights a strong performance of its existing refining unit after upgrading, an inevitable rise in opex and c. 6 months push-back on the opening of the…
Nouveau profil
La refonte en profondeur de Bourrelier Group suite à la cession de l’essentiel de ses actifs opérationnels est désormais prise en compte après publication des comptes 2017 décalés sur l’été…
H1 18: insignificant; some more time needed to reach the market
Crossject released its H1 18 results. Revenues reached €2,840k (vs €1,635k), operating result €-5,337k (vs €-4,256k), and the net result €-4,744k (vs €-3,360k). Net cash at the end of H1…
Orano as big bro’
Europlasma brings in Orano as a mighty partner to grow its hazardous waste management business. Europlasma has signed a frame agreement ready to be executed with Orano (ex Areva, state-owned)…
Robust earnings delivery in more choppy (FX)) waters
H1 18 earnings do confirm the ability of Chargeurs’ management to deliver in more adverse FX conditions and to stick to its quality growth promises. The up and coming group…
The market is within reach
We have fine-tuned our numbers on the back of the group’s latest comments as well as integrating the new NTE (New Therapeutic Entity) to be developed (Terbutaline), instead of Apomorphine…